How to buy Vaxart stock | $6.08

Vaxart, Inc is a biotechnology business based in the US. Vaxart shares (VXRT) are listed on the NASDAQ and all prices are listed in US Dollars. Vaxart employs 30 staff and has a trailing 12-month revenue of around USD$7.6 million.

How to buy shares in Vaxart

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Vaxart. Find the stock by name or ticker symbol: VXRT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vaxart reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$6.08, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Vaxart, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Vaxart. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Vaxart share price

Use our graph to track the performance of VXRT stocks over time.

Vaxart shares at a glance

• Key figures

Information last updated 2021-01-21.

Latest market close	USD$6.08
52-week range	USD$0.4488 - USD$17.15
50-day moving average	USD$7.0191
200-day moving average	USD$7.5541
Wall St. target price	USD$17.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.033

Buy Vaxart shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Vaxart stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Vaxart, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vaxart price performance over time

Historical closes compared with the close of $6.08 from 2020-10-16

1 week (2021-01-15)	-15.32%
1 month (2020-12-23)	-13.39%
3 months (2020-10-23)	7.80%
6 months (2020-07-23)	-56.10%

1 year (2020-01-23)	1,047.17%
2 years (2019-01-23)	235.91%
3 years (2018-01-23)	866.92%
5 years (2016-01-22)	251.45%

Vaxart financials

Revenue TTM	USD$7.6 million
Gross profit TTM	USD$-4,678,000
Return on assets TTM	-11.63%
Return on equity TTM	-32.9%
Profit margin	0%
Book value	$1.203
Market capitalisation	USD$720.5 million

TTM: trailing 12 months

Shorting Vaxart shares

There are currently 33.6 million Vaxart shares held short by investors – that's known as Vaxart's "short interest". This figure is 19.8% up from 28.0 million last month.

There are a few different ways that this level of interest in shorting Vaxart shares can be evaluated.

Vaxart's "short interest ratio" (SIR)

Vaxart's "short interest ratio" (SIR) is the quantity of Vaxart shares currently shorted divided by the average quantity of Vaxart shares traded daily (recently around 8.7 million). Vaxart's SIR currently stands at 3.84. In other words for every 100,000 Vaxart shares traded daily on the market, roughly 3840 shares are currently held short.

However Vaxart's short interest can also be evaluated against the total number of Vaxart shares, or, against the total number of tradable Vaxart shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaxart's short interest could be expressed as 0.31% of the outstanding shares (for every 100,000 Vaxart shares in existence, roughly 310 shares are currently held short) or 0.4016% of the tradable shares (for every 100,000 tradable Vaxart shares, roughly 402 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaxart.

Find out more about how you can short Vaxart stock.

Vaxart share dividends

We're not expecting Vaxart to pay a dividend over the next 12 months.

Have Vaxart's shares ever split?

Vaxart's shares were split on a 1:11 basis on 14 February 2018. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaxart shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Vaxart shares which in turn could have impacted Vaxart's share price.

Vaxart share price volatility

Over the last 12 months, Vaxart's shares have ranged in value from as little as $0.4488 up to $17.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaxart's is 0.4924. This would suggest that Vaxart's shares are less volatile than average (for this exchange).

Vaxart overview

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Vaxart, Inc. is headquartered in South San Francisco, California.

Frequently asked questions

• What percentage of Vaxart is owned by insiders or institutions?

  Currently 0.648% of Vaxart shares are held by insiders and 38.211% by institutions.

• How many people work for Vaxart?

  Latest data suggests 30 work at Vaxart.

• When does the fiscal year end for Vaxart?

  Vaxart's fiscal year ends in December.

• Where is Vaxart based?

  Vaxart's address is: 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

• What is Vaxart's ISIN number?

  Vaxart's international securities identification number is: US92243A2006

• What is Vaxart's CUSIP number?

  Vaxart's Committee on Uniform Securities Identification Procedures number is: 053761102